BRIEF published on 09/19/2024 at 18:05, 1 year 4 months ago ABIVAX: Number of shares and voting rights as of August 31, 2024 Euronext Paris Share Capital Voting Rights Biotechnology Abivax
BRIEF published on 09/09/2024 at 23:01, 1 year 4 months ago Statement by Marc de Garidel on Abivax's 2024 Half-Year Financial Report Financial Report Abivax Transparency IFRS Heritage
BRIEF published on 09/09/2024 at 22:40, 1 year 4 months ago ABIVAX presents its 2024 half-year results Cybersecurity Abivax Half-year Results Internal Control Failures
BRIEF published on 09/09/2024 at 22:06, 1 year 4 months ago Abivax financial results for the first half of 2024 Financial Results Biotechnology Abivax First Half Of 2024 Immune Mechanisms
PRESS RELEASE published on 09/09/2024 at 22:01, 1 year 4 months ago Abivax presents first-half 2024 financial results Abivax presents first-half 2024 financial results with a cash balance of EUR 222M at June 30, 2024. The company focuses on developing therapies for chronic inflammatory diseases Financial Results Abivax Therapeutics Chronic Inflammatory Diseases EUR 222M
BRIEF published on 08/29/2024 at 18:05, 1 year 5 months ago ABIVAX: Status of shares and voting rights as of July 31, 2024 Euronext Paris Voting Rights Actions Abivax Regulatory
BRIEF published on 08/06/2024 at 08:35, 1 year 5 months ago Abivax Reaches Key Milestone with Recruitment of 600 Patients for Phase 3 ABTECT Trial Patient Recruitment Abivax Obefazimod Ulcerative Colitis Clinical Test
PRESS RELEASE published on 08/06/2024 at 08:30, 1 year 5 months ago Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Abivax announces ABTECT Phase 3 Trial surpasses 600-patient enrollment milestone, on track for full enrollment by early Q1 2025. Trial trends align with previous observations Abivax Obefazimod Ulcerative Colitis ABTECT Phase 3 Trial Enrollment Milestone
BRIEF published on 07/23/2024 at 18:05, 1 year 6 months ago ABIVAX: Number of shares and voting rights as of June 30, 2024 Voting Rights Euronext Actions AMF Abivax
BRIEF published on 07/23/2024 at 18:05, 1 year 6 months ago ABIVAX: Half-yearly review of the liquidity contract as of June 30, 2024 Liquidity Contract Actions Financial Transactions Abivax First Half Of 2024
Published on 02/02/2026 at 00:05, 5 hours ago Resource Upgrade Drilling Begins on Challenger Open Pits
Published on 01/31/2026 at 03:15, 2 days 1 hour ago Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 01:40, 2 days 3 hours ago Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 02/02/2026 at 02:50, 2 hours 15 minutes ago Xinhua Silk Road: Ecosystem and sustainability redefine global automotive brand value: report
Published on 02/01/2026 at 20:25, 8 hours 40 minutes ago WHO Makes Historic Pivot to County-Level Governance, Validating "Bottom-Up" Climate-Health Model in Tropical Southern China
Published on 01/31/2026 at 15:54, 1 day 13 hours ago EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 1 day 16 hours ago JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 2 days 2 hours ago CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 17:45, 2 days 11 hours ago Schneider Electric launches a capital increase reserved for employees
Published on 01/29/2026 at 18:00, 3 days 11 hours ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 3 days 11 hours ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 3 days 11 hours ago Cegedim generated LFL revenue growth of 1.1% in 2025
